Please assess the completion status of the following clinical trial:

Trial Title: Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed high-risk or relapsed solid tumors or brain tumors, including:~  * Metastatic or relapsed Ewing's sarcoma~ * Metastatic or relapsed rhabdomyosarcoma~ * Refractory Wilms' tumor~ * Diffuse anaplastic Wilms' tumor~ * Stage III or IV neuroblastoma~ * Recurrent retinoblastoma~ * Metastatic or relapsed germ cell tumors~ * Metastatic or relapsed other soft tissue sarcomas~ * Small cell ovarian sarcoma~ * Metastatic or relapsed primitive neuroectodermal tumors of the bone~ * Recurrent brain tumors~ * Desmoplastic small round cell tumors~ * Recurrent or metastatic chordomas~ * Metastatic or relapsed hepatoblastoma~* Patients receive peripheral blood stem cell transplantation only if in complete remission or in very good partial remission with no disease progression~* Must have radiologic, nuclear image, or histologic verification of relapse~* Age 1 to 45~* Performance status:Karnofsky 70-100%~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 100,000/mm\^3~* Hemoglobin count at least 10 g/dL~* Bilirubin less than 2 times upper limit of normal (ULN)~* SGOT or SGPT less than 2.5 times ULN~* Creatinine less than 2 times ULN~* Creatinine clearance greater than 70 mL/min~* Cardiac shortening fraction greater than 30%~* Cardiac ejection fraction greater than 45%~* At least 1 week since prior hematopoietic growth factor and recovered~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* Recovered from any prior therapy~Exclusion Criteria:~* Osteogenic sarcoma~* Less than 4 months~* Uncontrolled bleeding~* Congestive heart failure~* Uncontrolled hypertension~* Asthma~* Pregnant or nursing~* Uncontrolled metabolic disease~* Active severe infection~* Allergy to aminothiol compounds~* Prior bone marrow transplantation~* Other concurrent investigational agents

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Solid/brain tumor patients (1-18 years) (Type: EXPERIMENTAL): Patients with solid tumor or brain tumor in the 1-18 years old stratum.
- Solid/brain tumor patients (19-45 years) (Type: EXPERIMENTAL): Patients with solid tumor or brain tumor in the 19-45 years old stratum.

Based on this trial design, predict the completion outcome and termination type (if applicable).